SR9009 demonstrates potent anticancer activity against PCS1, an aggressive prostate cancer subtype, by engaging the LXRα/FOXM1 pathway independently of REV-ERBs. The compound disrupts critical processes in cancer progression, including cell cycle regulation and migration, while enhancing apoptosis. Research shows that SR9009 suppresses PCS1-specific markers such as FOXM1, CCNB2, and CENPA, which are overexpressed in prostate cancer and linked to poor outcomes. Importantly, SR9009 does not harm normal prostate cells, underscoring its selectivity. The compound also halts tumor growth in vivo, offering substantial reductions in tumor volume. SR9009’s novel mechanism bypasses androgen receptor signaling, a key pathway in prostate cancer resistance, suggesting its utility in advanced cases. This makes SR9009 a promising therapeutic candidate for aggressive and treatment-resistant prostate cancer cases.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Intex Stenabolic by Intex Pharma, consult with your doctor or healthcare professional.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Home
